Skip to main content

The state of biosimilars in 2024

Although the U.S. biosimilars market has fallen short of expectations since its first product approval in 2015, more have poured onto the market after a slow start. Greater price competition could emerge as more biosimilars of each drug begin to launch.

included in this trendline
  • Sandoz spins out of Novartis as standalone generic drugmaker
  • CVS launches new venture in biosimilar drug experiment
  • Biosimilar makers split strategies in bid to take on top-selling Humira
Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.